Kinetics and performance of the Abbott Architect SARS-CoV-2 IgG antibody assay
Detection Principle
ImmunoAssay-Antibody
Target
IgG
Testing Method Category
Other Immuno assay
Testing Method
kit (Abbott)
Testing Method - Additional Info
Abbott Architect SARS-CoV-2 IgG assay
Reported Performance
Sensitivity: 44.4% (hospitalised PCR positive cases, <5 dpo), 12.5% (hospitalised PCR negative cases, < 5dpo), 32.6% (hospitalised PCR positive cases, 5-9 dpo), 28.6% (hospitalised PCR negative cases, 5-9 dpo), 65.2% (hospitalised PCR positive cases, 10-14 dpo), 80% (hospitalised PCR negative cases, 10-14 dpo), 66.7% (hospitalised PCR positive cases, 15-20 dpo), 50% (hospitalised PCR negative cases, 15-20 dpo), 100% (hospitalised PCR positive cases, >20 dpo), 83.3% (hospitalised PCR negative cases, >20dpo), 85.1% (healthcare workers, >20dpo)
Sample Size
241 subjects
Peer-reviewed
yes
The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements